Angle (AGL)

 

AGL Share PerformanceMore

52 week high80.00 15/06/17
52 week low32.27 07/09/17
52 week change 1.65 (3.35%)
4 week volume1,984,625 23/12/17

Media for (AGL)

Presenter: Andrew Newland, Chief Executive
09/10/2014

Latest NewsMore

Professor to present webinar on use of ANGLE's Parsortix

ANGLE has announced that Professor Stuart Martin from the University of Maryland School of Medicine, USA, will be p...

WEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS

RNS Number: 9414B Angle PLC 16 January 2018 For immediate release 16 January 2018 ANGLE plc ("the Company") WEBINAR: USING THE PARSORTIX TM SYSTEM TO IDENTIFY DRUGS THAT MAY ARREST CANCER METASTASIS ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that Professor Stuart Marti...

Notice of Results

RNS Number: 4781B Angle PLC 10 January 2018 For Immediate Release 10 January 2018 ANGLE plc ("ANGLE" or "the Company") Notification of Interim Results and Webcast ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 31 October 2017 on Wednesday 31 January 201...

ANGLE reports new research on Parsortix

ANGLE said it was delighted to announce that the University Medical Centre Hamburg-Eppendorf together with the Med...

ANGLE plc:Prostate cancer ARV7 treatment biomarker

RNS Number: 1632B Angle PLC 08 January 2018 For immediate release 8 January 2018 ANGLE plc ("the Company") RESEARCH DEMONSTRATES USE OF PARSORTIX TM LIQUID BIOPSY TO DETECT ARV7 IN PROSTATE CANCER AS A TREATMENT SELECTION BIOMARKER Parsortix-based ARV7 test may provide a wider understanding of ARV7...

Holding(s) in Company

RNS Number: 3649A Angle PLC 27 December 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ANGLE plc 1b. Please in...

Transfer of Lock-in Shares

RNS Number: 0247Z Angle PLC 12 December 2017 For immediate release 12 December 2017 ANGLE plc ("the Company") Transfer of Lock-in Shares ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that further to the announcement of 16 November 2017, finnCap and WG Partners have given their written consent to allo...

PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER

RNS Number: 7584Y Angle PLC 08 December 2017 For immediate release 8 December 2017 ANGLE plc ("the Company") GROUND-BREAKING WORK DEMONSTRATES POTENTIAL FOR PARSORTIX TM LIQUID BIOPSY TO REPLACE SOLID BIOPSY IN METASTATIC BREAST CANCER Direct comparison of a simple blood test processed with the Parso...

Fundamental DataMore

EPS-8.71
Dividend yield0 %

Latest discussion posts More

  • Rns

    Good PR from independent source but no move up
    16-Jan-2018
    millwallfan
  • The strange thing about this share.......

    ......is that there is a rise in SP following good news, and then literally the following day, there is a sell off - not vast numbers but significant in the context of this ...
    9-Jan-2018
    claude reins
  • Re: The benefits keep pouring in.........

    Agree Claude - we?ll put.
    8-Jan-2018
    autpaxautbellum

Users' HoldingsMore

Users who hold Angle also hold..

Codes & Symbols

ISINGB0034330679
SymbolsAGL, LSE:AGL, AGL.L, AGL:LN, LON:AGL, XLON:AGL

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account